Synthesis and antitumor activity of some indeno[1,2-b]quinoline-based bis carboxamides

被引:94
作者
Deady, LW [1 ]
Desneves, J
Kaye, AJ
Finlay, GJ
Baguley, BC
Denny, WA
机构
[1] La Trobe Univ, Dept Chem, Bundoora, Vic 3083, Australia
[2] Univ Auckland, Fac Med & Hlth Sci, Auckland Canc Soc, Res Lab, Auckland 1000, New Zealand
关键词
D O I
10.1016/S0968-0896(00)00039-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of bis(11-oxo-1 1H-indeno[1,2-b]quinoline-6-carboxamides) linked through the B-carboxamides were prepared by coupling the requisite acid imidazolides with Various diamines. Compounds with mono-cationic linker chains were more potent cytotoxins than the corresponding monomer in a panel of rodent and human cell lines: while those with the dicationic linker chains (CH2)(2)NR(CH2)(2)NR(CH2)(2) and (CH2)(2)NR(CH2)(3)NR(CH2)(2) showed extraordinarily high potencies (for example, IC(50)s of 0.18-1.4 nM against human Jurkat leukemia; up to 1000-fold more potent than the parent monomer). As seen previously in the monomeric series, small, lipophilic 4-substituents significantly increased potency in cell culture. The dimeric compounds were all slightly to significantly more potent in the mutant JL(A) and JL(D) cell lines that under-express topo II, suggesting that this enzyme is not their primary target. An Il-imino-linked dimer was much less active, and an asymmetric indeno[1,2-b]quinoline-6-carboxamide/naphthalimide dimer was less active than the comparable symmetric bis(indeno[1,2-b]quinoline-6-carboxamide). Selected analogues were active against sub-cutaneously implanted colon 38 tumors in mice? giving growth delays comparable to that of the clinical topo I inhibitor irinotecan at up to 10-fold lower doses. These compounds form an interesting new class of putative topo I inhibitors. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:977 / 984
页数:8
相关论文
共 26 条
[1]   Benzimidazo[1,2-c]quinazoline dimers as potential antitumor agents [J].
Brana, MF ;
deVega, MJP ;
Perron, D ;
Conlon, D ;
Bousquet, PF ;
Robinson, SP .
JOURNAL OF HETEROCYCLIC CHEMISTRY, 1997, 34 (03) :807-812
[2]  
Brana MF, 1996, ANTI-CANCER DRUG DES, V11, P297
[3]   Chromophore-modified bis-naphthalimides: Synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones [J].
Brana, MF ;
Castellano, JM ;
Perron, D ;
Maher, C ;
Conlon, D ;
Bousquet, PF ;
George, J ;
Qian, XD ;
Robinson, SP .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (04) :449-454
[4]   HYDROBORATION .3. THE REDUCTION OF ORGANIC COMPOUNDS BY DIBORANE, AN ACID-TYPE REDUCING AGENT [J].
BROWN, HC ;
RAO, BCS .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1960, 82 (03) :681-686
[5]   Structure-based design fill of a new bisintercalating anthracycline antibiotic [J].
Chaires, JB ;
Leng, FF ;
Przewloka, T ;
Fokt, I ;
Ling, YH ;
PerezSoler, R ;
Priebe, W .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (03) :261-266
[6]   BISIMIDAZOACRIDONES AND RELATED-COMPOUNDS - NEW ANTINEOPLASTIC AGENTS WITH HIGH SELECTIVITY AGAINST COLON TUMORS [J].
CHOLODY, WM ;
HERNANDEZ, L ;
HASSNER, L ;
SCUDIERO, DA ;
DJURICKOVIC, DB ;
MICHEJDA, CJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (16) :3043-3052
[7]   Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: A new class of putative topoisomerase inhibitors [J].
Deady, LW ;
Kaye, AJ ;
Finlay, GJ ;
Baguley, BC ;
Denny, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (13) :2040-2046
[8]   Ring-substituted 11-oxo-11H-indeno[1,2-b]quinoline-6-carboxamides with similar patterns of cytotoxicity to the dual topo I/II inhibitor DACA [J].
Deady, LW ;
Desneves, J ;
Kaye, AJ ;
Thompson, M ;
Finlay, GJ ;
Baguley, BC ;
Denny, WA .
BIOORGANIC & MEDICINAL CHEMISTRY, 1999, 7 (12) :2801-2809
[9]   MULTIPLE PATTERNS OF RESISTANCE OF HUMAN LEUKEMIA-CELL SUBLINES TO AMSACRINE ANALOGS [J].
FINLAY, GJ ;
BAGULEY, BC ;
SNOW, K ;
JUDD, W .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (08) :662-667
[10]  
FINLAY GJ, 1994, ONCOL RES, V6, P33